Indeed, this marked statin-induced shift in circulating levels of multiple molecular lipid species toward levels in the control group suggests that pitavastatin therapy may reduce risk of dysglycemia and T2D associated with the atherogenic mixed dyslipidemia characteristic of insulin-resistant states. Here, INS is linked to type 2 diabetes mellitus.